- Home
- OXY vs TEVA Comparison
OXY vs TEVA Comparison
Compare OXY & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OXY | TEVA |
|---|---|---|
| Founded | 1920 | 1901 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.3B | 40.5B |
| IPO Year | 1995 | 1996 |
Fundamental Metrics
Financial Performance| Metric | OXY | TEVA |
|---|---|---|
| Price | $61.30 | $37.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 21 | 8 |
| Target Price | ★ $57.71 | $38.63 |
| AVG Volume (30 Days) | ★ 7.9M | 5.6M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.71% | N/A |
| EPS Growth | N/A | ★ 183.45 |
| EPS | ★ 5.89 | N/A |
| Revenue | ★ $21,593,000,000.00 | N/A |
| Revenue This Year | $14.12 | N/A |
| Revenue Next Year | N/A | $2.97 |
| P/E Ratio | $10.44 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $38.80 | $17.82 |
| 52 Week High | $67.45 | $37.83 |
Technical Indicators
Market Signals| Indicator | OXY | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 67.63 | 66.00 |
| Support Level | $52.89 | $30.42 |
| Resistance Level | $67.45 | N/A |
| Average True Range (ATR) | 1.24 | 0.87 |
| MACD | 0.39 | 0.15 |
| Stochastic Oscillator | 91.40 | 89.21 |
Price Performance
Historical ComparisonAbout OXY Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2025, the company reported net proved reserves of 4.6 billion barrels of oil equivalent. Net production averaged 1.4 million barrels of oil equivalent per day in 2025 at a ratio of roughly 74% oil and natural gas liquids and 26% natural gas.
About TEVA Teva Pharmaceutical Industries Limited
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.